Compare General Dynamics Corporation (GD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Novo Nordisk A/S — how do they compare? General Dynamics Corporation trades at $331.27 (market cap $89.26B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 85 Days and Novo Nordisk A/S for 116 Days on average.
| GD | NVO | |
|---|---|---|
Market Cap | $89.26B | $165.31B |
Volume | 1,496,273 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $395.97 | $63.98 |
52-Week Low | $312.53 | $35.29 |
Typical Hold Time | 85 Days | 116 Days |
Enterprise Value | $94.40B | $179.56B |
Dividend Yield | 1.93% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $329.9, up 1.0% over 24 hours, with a bearish technical signal but strong fundamentals. The company reported consistent earnings beats, with Q2 2026 EPS of $4.24 exceeding the $3.96 estimate, and maintains robust profitability with an 8.18% net margin. Revenue grew to $52.55 billion in 2025, supported by defense contract demand. Analyst consensus is bullish with a $420.57 price target, though technical indicators show near-term resistance at $332.
The outlook for GD is positive, driven by Pentagon spending and dividend reliability, but risks include defense budget volatility and competitive pressures. The stock offers value with a P/E of 20.12 and a 17.8% ROE, yet investors should monitor debt levels and geopolitical factors affecting defense contracts.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
